Brian T. Hopkins - Concepedia

Author

Brian T. Hopkins

Biogen (United States)ORCID

Also Known As

B. T. Hopkins, Brian Hopkins, Brian T Hopkins, Brian T. Hopkins

Publications

811

Citations

H-Index

Concepts

All Affiliations

Biogen (United States)Imperial College London Sunesis (United States)

About

Brian T. Hopkins is an author at Biogen (United States) specializing in drug discovery, engineering, and biomolecular engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	3	3	88
2	Medicine	3	3	75
3	Biochemistry	3	3	48
4	Biomolecular Engineering	3	3	88
5	Natural Sciences	1	1	18

Brian T. Hopkins

Publications

656

Citations

H-Index

Page 1

	Year	Citations
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases D.J. Marcotte, Yuting Liu, Robert M. Arduini, Protein Science	2010	148
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy Rui Li, Hao Tang, Jeremy C. Burns, Acta Neuropathologica	2022	64
ROMPgel-Supported Triphenylphosphine with Potential Application in Parallel Synthesis Erik Årstad, Anthony G. M. Barrett, Brian T. Hopkins, Organic Letters	2002	63
Parallel Synthesis of Terminal Alkynes Using a ROMPgel-Supported Ethyl 1-Diazo-2-oxopropylphosphonate Anthony G. M. Barrett, Brian T. Hopkins, Andrew C. Love, Organic Letters	2004	46
ROMPgel-supported biphenyl and naphthalene: reagents for lithiation reactions with minimal purification Thomas Arnauld, Anthony G. M. Barrett, Brian T. Hopkins Tetrahedron Letters Novel OrganocatalystsRompgel-supported BiphenylEngineeringMinimal PurificationOrganic Chemistry	2002	43
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling Kate L. Henry, Debra Kellner, Bekim Bajrami, Science Signaling	2018	38
Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Journal of Medicinal Chemistry	2020	36
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis Brian T. Hopkins, Eris Bame, Bekim Bajrami, Journal of Medicinal Chemistry ImmunologyNeurological ProgressImmunotherapySelective Btk InhibitorReceptor Tyrosine Kinase	2021	36
Facile and purification free synthesis of Mosher amides utilizing a ROMPgel supported reagent Thomas Arnauld, Anthony G. M. Barrett, Brian T. Hopkins, Tetrahedron Letters Combinatorial ChemistryMosher AmidesEngineeringOrganic ChemistrySynthetic Chemistry	2001	30
Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation Minke E. Binnerts, Kevin L. Otipoby, Brian T. Hopkins, Molecular Cancer Therapeutics ImmunologyPharmacotherapyImmunotherapyTumor BiologySns-062 Activity	2015	24

Page 1